SLE Remission: The Treat-to-Target Approach

“There is more work to be done, and we need more practical scoring both for clinical trials and clinical practice.”

Susan Bernstein is a freelance journalist based in Atlanta.

References

1. Bexelius C, Wachtmeister K, Skare P, et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): A Swedish nationwide study based on patient reports. Lupus. 2013 Jul;22(8):793–801.
2. D’Cruz DP, Houssiau FA. The Euro-Lupus Nephritis Trial: The development of the sequential treatment protocol. Lupus. 2009 Sep;18(10):875–877.
3. Furie R, Petri M, Zamani O, et al. A phase-III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–3930.
4. Smolen JS, Breedveid FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3–15.
5. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014 Apr; 73(6):958–966.
6. Van Vollenhoven RF, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554–561.
7. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615–1621.